First Citizens Bank & Trust CO Innoviva, Inc. Transaction History

First Citizens Bank & Trust CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 26, 2022	SELL	$15.39 - $20.25 $215,937 - $284,127	-14,031 Closed	0 $0
Q4 2021 Mar 11, 2022	SELL	$15.91 - $18.72 $33,729 - $39,686	-2,120 Reduced 13.13%	14,031 $242,000
Q3 2021 Oct 15, 2021	SELL	$13.06 - $17.24 $39 - $51	-3 Reduced 0.02%	16,151 $270,000
Q2 2021 Jul 14, 2021	BUY	$11.45 - $13.96 $184,963 - $225,509	16,154 New	16,154 $217,000
Q2 2020 Jul 15, 2020	SELL	$11.49 - $15.26 $147,451 - $195,831	-12,833 Closed	0 $0
Q1 2020 Apr 17, 2020	BUY	$8.11 - $15.23 $12,838 - $24,109	1,583 Added 14.07%	12,833 $151,000
Q4 2019 Jan 15, 2020	BUY	$10.28 - $14.38 $115,650 - $161,775	11,250 New	11,250 $159,000

229

79.2M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.33B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of First Citizens Bank & Trust CO, based on Form 13F filings with the SEC.

Stay updated on First Citizens Bank & Trust CO with notifications on news.